Butanamide,3-[[(2R)-2-hydroxypropyl]amino]-3-methyl-N-[(3R)-2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3-yl]- (145455-35-2)

Identification
Name:	Butanamide,3-[[(2R)-2-hydroxypropyl]amino]-3-methyl-N-[(3R)-2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3-yl]-
Synonyms:	Butanamide,3-[(2-hydroxypropyl)amino]-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3-yl]-,[R-(R,R)]-; 1H-1-Benzazepine, butanamide deriv.; L 692585
CAS:	145455-35-2
Molecular Formula:	C32H37 N7 O3
Molecular Weight:	0
InChI:	InChI=1/C32H37N7O3/c1-21(40)19-33-32(2,3)18-29(41)34-27-17-16-24-8-4-7-11-28(24)39(31(27)42)20-22-12-14-23(15-13-22)25-9-5-6-10-26(25)30-35-37-38-36-30/h4-15,21,27,33,40H,16-20H2,1-3H3,(H,34,41)(H,35,36,37,38)/t21-,27-/m1/s1
Molecular Structure:
Properties
Flash Point:	°C
Boiling Point:	°Cat760mmHg
Density:	1.31g/cm³
Refractive index:	1.66
Biological Activity:	Highly potent, non-peptide ghrelin receptor (GHS-R1a) agonist (K i = 0.8 nM). Increases plasma GH levels in vivo and is 2- to 2.5-fold more potent than GHRP-6.
Flash Point:	°C
Safety Data